Skip to main content

Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19.

Publication ,  Journal Article
Vasquez, CR; Gupta, S; Miano, TA; Roche, M; Hsu, J; Yang, W; Holena, DN; Reilly, JP; Schrauben, SJ; Leaf, DE; Shashaty, MGS ...
Published in: Chest
September 2021

BACKGROUND: Subphenotypes have been identified in patients with sepsis and ARDS and are associated with different outcomes and responses to therapies. RESEARCH QUESTION: Can unique subphenotypes be identified among critically ill patients with COVID-19? STUDY DESIGN AND METHODS: Using data from a multicenter cohort study that enrolled critically ill patients with COVID-19 from 67 hospitals across the United States, we randomly divided centers into discovery and replication cohorts. We used latent class analysis independently in each cohort to identify subphenotypes based on clinical and laboratory variables. We then analyzed the associations of subphenotypes with 28-day mortality. RESULTS: Latent class analysis identified four subphenotypes (SP) with consistent characteristics across the discovery (45 centers; n = 2,188) and replication (22 centers; n = 1,112) cohorts. SP1 was characterized by shock, acidemia, and multiorgan dysfunction, including acute kidney injury treated with renal replacement therapy. SP2 was characterized by high C-reactive protein, early need for mechanical ventilation, and the highest rate of ARDS. SP3 showed the highest burden of chronic diseases, whereas SP4 demonstrated limited chronic disease burden and mild physiologic abnormalities. Twenty-eight-day mortality in the discovery cohort ranged from 20.6% (SP4) to 52.9% (SP1). Mortality across subphenotypes remained different after adjustment for demographics, comorbidities, organ dysfunction and illness severity, regional and hospital factors. Compared with SP4, the relative risks were as follows: SP1, 1.67 (95% CI, 1.36-2.03); SP2, 1.39 (95% CI, 1.17-1.65); and SP3, 1.39 (95% CI, 1.15-1.67). Findings were similar in the replication cohort. INTERPRETATION: We identified four subphenotypes of COVID-19 critical illness with distinct patterns of clinical and laboratory characteristics, comorbidity burden, and mortality.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Chest

DOI

EISSN

1931-3543

Publication Date

September 2021

Volume

160

Issue

3

Start / End Page

929 / 943

Location

United States

Related Subject Headings

  • United States
  • SARS-CoV-2
  • Respiratory System
  • Renal Replacement Therapy
  • Pandemics
  • Middle Aged
  • Male
  • Humans
  • Female
  • Critical Illness
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vasquez, C. R., Gupta, S., Miano, T. A., Roche, M., Hsu, J., Yang, W., … STOP-COVID Investigators, . (2021). Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19. Chest, 160(3), 929–943. https://doi.org/10.1016/j.chest.2021.04.062
Vasquez, Charles R., Shruti Gupta, Todd A. Miano, Meaghan Roche, Jesse Hsu, Wei Yang, Daniel N. Holena, et al. “Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19.Chest 160, no. 3 (September 2021): 929–43. https://doi.org/10.1016/j.chest.2021.04.062.
Vasquez CR, Gupta S, Miano TA, Roche M, Hsu J, Yang W, et al. Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19. Chest. 2021 Sep;160(3):929–43.
Vasquez, Charles R., et al. “Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19.Chest, vol. 160, no. 3, Sept. 2021, pp. 929–43. Pubmed, doi:10.1016/j.chest.2021.04.062.
Vasquez CR, Gupta S, Miano TA, Roche M, Hsu J, Yang W, Holena DN, Reilly JP, Schrauben SJ, Leaf DE, Shashaty MGS, STOP-COVID Investigators. Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19. Chest. 2021 Sep;160(3):929–943.

Published In

Chest

DOI

EISSN

1931-3543

Publication Date

September 2021

Volume

160

Issue

3

Start / End Page

929 / 943

Location

United States

Related Subject Headings

  • United States
  • SARS-CoV-2
  • Respiratory System
  • Renal Replacement Therapy
  • Pandemics
  • Middle Aged
  • Male
  • Humans
  • Female
  • Critical Illness